IBRX’s ANKTIVA Achieves 700% Revenue Growth, First Global Lung Cancer Approval, and Rapid Expansion Across 33 Countries

Exceptional Revenue and Unit Sales Growth Propel ImmunityBio’s Momentum

ImmunityBio (NASDAQ: IBRX) is defying industry odds after reporting full-year 2025 net product revenue of $113 million for ANKTIVA—an eye-catching 700% increase from the prior year. The revenue jump was supported by a 750% surge in unit sales and a 20% rise in net product revenue quarter-over-quarter, highlighting a sustained commercial ramp that few biotech peers can match.

This sales momentum suggests rapid clinical adoption, with ANKTIVA’s reach quickly extending from its initial U.S. bladder cancer approval to broad international commercial activities.

Landmark Global Approvals and First-Ever Authorization in Lung Cancer

Driven by robust clinical data, ANKTIVA has been approved in 33 countries within two years—across the U.S., U.K., European Union, and Saudi Arabia. Notably, Saudi Arabia’s SFDA granted the world’s first approval for ANKTIVA in combination with checkpoint inhibitors in metastatic non-small cell lung cancer (NSCLC), with a commercial launch targeted within 60 days. This marks a crucial step beyond bladder cancer and solidifies ANKTIVA’s role in multiple solid tumor indications, along with label expansion efforts in both oncology and lymphopenia.

The company is actively pursuing additional approvals—including discussions with the U.S. FDA and planned submissions to many other jurisdictions through 2026—underscoring its ambition to position ANKTIVA as a global immunotherapy cornerstone.

Investments in R&D and a Robust Pipeline Fuel Future Expansion

While the company continues to operate at a loss (net loss of $351.40 million for 2025, narrowed from $413.60 million in 2024), the higher R&D spend signals a strong commitment to future market expansion. ImmunityBio is advancing over 30 clinical trials targeting 10 tumor types—including pivotal randomized studies in bladder cancer, lung cancer, pancreatic cancer, and beyond. The research focus, complemented by partnerships with Accord Healthcare and MENA-region entities, positions the company for additional regulatory wins and new market launches.

Long-Term Patent Portfolio and Global Commercial Infrastructure Underpin Exclusivity

Multiple patents extending to at least 2035 protect the combination of ANKTIVA with checkpoint inhibitors, offering years of exclusivity in key oncology markets. ImmunityBio has also built a formidable global commercial footprint, with an 85-person European salesforce, subsidiaries in strategic centers like Dublin and Saudi Arabia, and distribution partnerships spanning 33 countries. This infrastructure will be critical to scaling future product launches and maintaining growth momentum.

Financial Health: Strong Cash Reserves Sustain Operational Agility

ImmunityBio closed 2025 with $242.82 million in cash, cash equivalents, and marketable securities, providing the company with runway to support continued R&D and the expansion of ANKTIVA’s commercial footprint. Importantly, SG&A expenses fell (down $18.80 million year-over-year), further offsetting higher research outlays.

Outlook: ANKTIVA as the Cornerstone of an Expanding Oncology Platform

With record-setting regulatory expansion, substantial growth in revenue and unit sales, and a clear focus on label expansion, ImmunityBio is actively shaping the future of immunotherapy. The company’s deep clinical pipeline, patent-protected assets, and global infrastructure suggest that further milestones—particularly in lung cancer and lymphopenia—could be on the horizon. Investors should watch closely as IBRX continues to transform from a single-product story into a diversified global oncology platform.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI